GSK 捜し出すs U.S. 是認 for shingles ワクチン Shingrix
LONDON, Oct 24 (Reuters) - GlaxoSmithKline said on Monday it had とじ込み／提出するd its shingles ワクチン Shingrix for U.S. regulatory 是認, bringing the 可能性のある blockbuster a step closer to market.
Shingrix is 見解（をとる）d by 分析家s as の中で the British drugmaker's most 約束ing 実験の 製品s, since it has shown greater 保護 の中で older 受取人s than Merck & Co's 競争相手 発射 Zostavax.
GSK said it planned to とじ込み／提出する Shingrix for European and Canadian 是認 before the end of this year, with Japan に引き続いて in 2017. (報告（する）／憶測ing by Ben Hirschler; Editing by Susan Fenton)
